Mechanism of Action
PTH1R R0 Conformation Selectivity
Abaloparatide binds the PTH1R with a different receptor conformational selectivity than teriparatide. It preferentially stabilizes the R0 conformation (uncoupled from Gs protein), producing a more transient cAMP signal compared to teriparatide's prolonged cAMP via the RG conformation. This shorter cAMP pulse duration is hypothesized to favor osteoblast anabolic signaling (Wnt pathway, reduced osteoblast apoptosis) while minimizing prolonged RANKL-mediated osteoclast activation. Whether this translates to a clinically meaningful "anabolic window" advantage is debated.
Bone Formation and Remodeling
Like teriparatide, abaloparatide stimulates osteoblast differentiation, activity, and survival. Biochemical markers of bone formation (P1NP, osteocalcin) rise within 1-3 months. BMD increases are seen at spine (11% at 18 months in ACTIVE trial) and hip (4%). The ratio of bone formation to resorption markers at 3 months is more favorable for abaloparatide than teriparatide in head-to-head comparisons, potentially reflecting the proposed reduced resorptive drive.
Transient cAMP and Osteocyte Signaling
PTH1R on osteocytes regulates sclerostin production; receptor activation reduces sclerostin, lifting its inhibition of Wnt signaling and promoting bone formation throughout the skeleton. Abaloparatide's brief cAMP signal may reduce the rebound sclerostin increase that occurs between doses with teriparatide, potentially sustaining Wnt-driven bone formation more consistently across the 24-hour dosing interval.
Research Summary
ACTIVE Trial (Pivotal)
Standard of CareThe ACTIVE trial (n=2463, 18 months) showed abaloparatide 80 mcg/day reduced vertebral fractures by 86% and non-vertebral fractures by 43% versus placebo. Compared to the open-label teriparatide arm, abaloparatide showed numerically fewer non-vertebral fractures and similar vertebral fracture reduction. Spine BMD increased 11.2% vs 10.5% (teriparatide) and hip BMD increased 4.2% vs 3.2%, suggesting a modest hip BMD advantage.
ATOM Extension Trial
ClinicalThe ATOM trial followed ACTIVE completers through 24 months of denosumab after abaloparatide or teriparatide. The abaloparatide-to-denosumab sequence produced greater total hip and femoral neck BMD gains than teriparatide-to-denosumab, suggesting abaloparatide may prime the skeleton for greater antiresorptive benefit when sequenced appropriately.
Hypercalcemia Comparison
ClinicalA notable finding was lower transient hypercalcemia with abaloparatide (3% grade 1) versus teriparatide (6% grade 1) in ACTIVE trial post-dose monitoring (1 hour after injection). This difference, attributed to reduced direct PTH1R-mediated calcium reabsorption in kidney (since abaloparatide binds R0 conformation with lower renal Ca reabsorption), is a potential tolerability advantage in patients with calcium metabolism concerns.
Calculate your Abaloparatide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Osteoporosis treatment | 80 mcg SC once daily | Once daily; maximum 2 years cumulative | SC (periumbilical abdomen) |
| Head-to-head vs teriparatide (ATOM) | 80 mcg SC abaloparatide vs 20 mcg SC teriparatide | Once daily x 18 months then denosumab | SC injection |
| PTH1R conformation study | 1-1000 nM in receptor binding assay | Single concentration-response | In vitro receptor preparation |
Rotate injection sites. Sit or lie down for 30 minutes after injection (hypotension risk). Monitor calcium at 1 and 3 months. Follow with antiresorptive (bisphosphonate or denosumab) to preserve gains.
Interactions
Safety Profile
Abaloparatide's adverse effect profile is similar to teriparatide with some differences. Hypercalcemia is less frequent (3% vs 6% for teriparatide at 1 hour post-dose). Orthostatic hypotension and dizziness occur in the hour post-injection, patients should sit or lie down for 30 minutes. Nausea, fatigue, and injection site reactions (pain, erythema) are common. Osteosarcoma risk carries the same black box warning as teriparatide (based on rat studies at supraphysiological doses; not observed in humans). Contraindicated in hypercalcemia, Paget disease, open epiphyses, and prior skeleton irradiation.
References
- [1]Miller PD, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial (ACTIVE). JAMA. 2016;316:722-733.
- [2]Leder BZ, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study). Lancet. 2015.
- [3]Hattersley G, et al. Differentiating abaloparatide and teriparatide by their actions on the PTH1R receptor. J Bone Miner Res. 2016.